Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension by Barbara Girerd et al.
Girerd et al. Respiratory Research 2010, 11:73
http://respiratory-research.com/content/11/1/73
Open AccessR E S E A R C HResearchAbsence of influence of gender and BMPR2 
mutation type on clinical phenotypes of 
pulmonary arterial hypertension
Barbara Girerd1,2,3, David Montani*1,2,3, Mélanie Eyries4, Azzedine Yaici1,2,3, Benjamin Sztrymf1,2,3, Florence Coulet4, 
Olivier Sitbon1,2,3, Gérald Simonneau1,2,3, Florent Soubrier4 and Marc Humbert1,2,3
Abstract
Background: Previous studies indicate that patients with pulmonary arterial hypertension (PAH) carrying a mutation in 
the bone morphogenetic protein receptor type 2 (BMPR2) gene, develop the disease 10 years earlier than non-carriers, 
and have a more severe hemodynamic compromise at diagnosis. A recent report has suggested that this may only be 
the case for females and that patients with missense mutations in BMPR2 gene have more severe disease than patients 
with truncating mutations.
Methods: We reviewed data from all patients with PAH considered as idiopathic and patients with a family history of 
PAH, who underwent genetic counselling in the French PAH network between January, 1st 2004 and April, 1st 2010. We 
compared clinical, functional, and hemodynamic characteristics between carriers and non-carriers of a BMPR2 
mutation, according to gender or BMPR2 mutation type.
Results: PAH patients carrying a BMPR2 mutation (n = 115) were significantly younger at diagnosis than non-carriers (n 
= 267) (35.8 ± 15.4 and 47.5 ± 16.2 respectively, p < 0.0001). The presence of a BMPR2 mutation was associated with a 
younger age at diagnosis in females (36.4 ± 14.9 in BMPR2 mutation carriers and 47.4 ± 15.8 in non-carriers, p < 0.0001), 
and males (34.6 ± 16.8 in BMPR2 mutation carriers and 47.8 ± 17.1 in non-carriers, p < 0.0001). BMPR2 mutation carriers 
had a more severe hemodynamic compromise at diagnosis, but this was not influenced by gender. No differences in 
survival and time to death or lung transplantation were found in male and female PAH patients carrying a BMPR2 
mutation. No differences were observed in clinical outcomes according to the type of BMPR2 mutations (missense, 
truncating, large rearrangement or splice defect).
Conclusion: When compared to non-carriers, BMPR2 mutation carriers from the French PAH network are younger at 
diagnosis and present with a more severe hemodynamic compromise, irrespective of gender. Moreover, BMPR2 
mutation type had no influence on clinical phenotypes in our patient population.
Background
Pulmonary arterial hypertension (PAH) is a severe dis-
ease affecting small pulmonary arteries, with a progres-
sive remodeling leading to elevated pulmonary vascular
resistance and right ventricular failure [1-3]. PAH can be
idiopathic, heritable or associated with drug or toxin
exposure or other conditions such as connective tissue
diseases, human immunodeficiency virus infection, con-
genital heart diseases, and portal hypertension [1,2]. Ger-
mline mutations in the bone morphogenetic protein
receptor type 2 (BMPR2) gene are detected in 10 to 40%
of idiopathic PAH and in 58% to 74% of patients with a
family history of PAH [4-6]. Accumulated evidence indi-
cates that PAH patients carrying a BMPR2 mutation
develop PAH approximately 10 years earlier than non-
carriers, with a more severe hemodynamic compromise
at diagnosis, and are less likely to respond to acute vaso-
dilator testing [4-6]. In addition, few cases of PAH in
ACVRL1 and Endoglin mutants have been reported [6-9].
PAH patients with an ACVRL1 mutation are character-
ized by a younger age at diagnosis and death, as com-
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mutation [6].
A recent report in Respiratory Research by Austin and
colleagues [10] showed that PAH patients with missense
mutations in BMPR2 gene had more severe disease than
patients with truncating mutation with a significant
younger age at diagnosis, a younger age at death and a
shorter survival from diagnosis to death or lung trans-
plantation. Moreover, they demonstrated a statistically
significant difference in age at diagnosis between carriers
and non-carriers, and subgroup analysis revealed this to
be the case only for females [10].
To test the influence of gender in patients from the
French PAH network, we decided to compare clinical,
functional, and hemodynamic characteristics between
PAH patients carriers of a BMPR2 mutation and patients
without identified mutation, according to gender. To
analyse the influence of the type of BMPR2 mutation in
clinical outcomes of PAH, clinical phenotypes were com-
pared between BMPR2 missense mutation carriers,
BMPR2 truncating mutation carriers and patients carri-




We reviewed data from all patients with PAH considered
to be idiopathic and patients with a family history of
PAH, who were tested for BMPR2 and ACVRL1 muta-
tions, seen in the French PAH network (Université Paris-
Sud 11, Hôpital Antoine-Béclère, Clamart, France)
between January, 1st 2004 and April, 1st 2010. In accor-
dance with the guidelines of the American College of
Chest Physicians [11], patients tested for BMPR2 or
ACVRL1 mutations signed written informed consent and
underwent genetic counselling. A diagnosis of PAH was
defined by hemodynamic measurement during right-
heart catheterization (see below). Idiopathic PAH was
recognized after ruling out all causes of pulmonary
hypertension, summarized in the revised classification,
and by determining no other PAH cases in the family [4].
Familial PAH was recognised if there was more than one
confirmed case in the family. PAH patients with an
ACVRL1 mutation (n = 9), a suspected or confirmed pul-
monary veno-occlusive disease (n = 55), or a family his-
tory of PAH without identification of either BMPR2 or
ACVRL1 mutation (n = 13) were excluded in order to
limit the risk of misclassification. All clinical characteris-
tics at PAH diagnosis and follow-up were stored in the
Registry of the French PAH Network [12]. This Registry
was set up in agreement with French bioethics laws
(French Commission Nationale de l'Informatique et des
libertés), and patients gave their consent to be included
[4,12].
Hemodynamic measurements and 6-minute walk distance
PAH was defined as a mean pulmonary arterial pressure
(mPAP) ≥25 mmHg associated with a normal pulmonary
capillary wedge pressure (PCWP). Hemodynamic evalua-
tion by right heart catheterization was performed at base-
line in all subjects according to our previously described
protocol [13,14]. Patients with left heart diseases and pas-
sive increase of mPAP secondary to increase cardiac out-
put were excluded from the study. The mPAP, PCWP,
right atrial pressure (RAP) and mixed venous oxygen sat-
uration (SvO2) were recorded during right-heart cathe-
terization. Cardiac output (CO) was measured by the
standard thermodilution technique. The cardiac index
(CI) was calculated as the CO divided by the body surface
area and systolic index as the CI divided by cardiac fre-
quency. Indexed total pulmonary resistance (TPRi) and
indexed pulmonary vascular resistance (PVRi) were cal-
culated as (mPAP)/CI and (mPAP-PCWP)/CI respec-
tively, and results were expressed as mmHg/L/min/m².
Baseline hemodynamic data and response to short-term
vasodilator nitric oxide (NO) obtained through right
heart catheterization were performed for all subjects. A
NO challenge (10 ppm for 5-10 minutes) was used and a
positive acute response was defined as a decrease in
mPAP of more than 10 mmHg compared to the baseline
mPAP to reach a mPAP lower than 40 mmHg associated
with a normal or increased CO, as previously described
[1,2,13]. A non-encouraged 6-minute walk test according
to the American Thoracic Society recommendations was
performed [15].
Screening of point mutations and large rearrangements of 
ACVRL1 and BMPR2 genes
Human genomic DNA was prepared from whole blood
samples. Amplification of the entire coding sequence and
intronic junctions of the ACVRL1 and BMPR2 genes was
performed on 50 ng of genomic DNA from each individ-
ual. Genetic variation of BMPR2 and ACVRL1 sequence
and rearrangements of one or more exons of the ACVRL1
and BMPR2 genes was detected as previously described
[4,6].
Statistical analysis
We compared demographic and clinical features, age at
diagnosis of PAH, according to gender and BMPR2 muta-
tion status, or according to type of BMPR2 mutation with
the use of Chi-2, ANOVA post Hoc test and Mann Whit-
ney as appropriate. Survival and time to death or lung
transplantation were analysed with the use of Kaplan
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to indicate statistical significance.
Results
Influence of gender on phenotypes
In the French PAH network, 382 PAH patients with idio-
pathic PAH or with a family history of PAH, correspond-
ing to 113 males and 269 females, were screened for
BMPR2 mutations. Interestingly, the same proportion of
BMPR2 mutation carriers was observed in males (n = 33,
30.1%) and females (n = 81, 30.1%). As previously
reported [4,6,10], PAH patients carrying a BMPR2 muta-
tion were significantly younger at diagnosis than non-car-
riers (35.8 ± 15.4 and 47.5 ± 16.2, p < 0.0001). This was
the case in females (36.4 ± 14.9 in BMPR2 mutation carri-
ers and 47.4 ± 15.8 in non-carriers, p < 0.0001) (Figure 1),
as well as in males (34.6 ± 16.8 in BMPR2 mutation carri-
ers and 47.8 ± 17.1 in non-carriers, p < 0.0001) (Figure 1).
As previously reported [4,6], BMPR2 mutation carriers
had a more severe hemodynamic compromise at diagno-
sis, but this was not influenced by gender (Table 1).
Although BMPR2 mutation carriers are younger at diag-
nosis than non-carriers, survival and time to death or
lung transplantation is broadly similar between carriers
and non-carriers, suggesting a similar evolution of estab-
lished disease in heritable and idiopathic PAH (Figure
2A). When comparing survival and time to death or lung
transplantation in BMPR2 mutation carriers and non-
carriers according to gender, no statistically significant
differences were observed between males and females
(Figure 3A and 3B). Although males and females have the
same age at diagnosis (43.8 ± 18.0 and 44.2 ± 16.3 respec-
tively, p = 0.86), and have also the same age at death (50.4
± 22.9 and 49.0 ± 16.9 respectively, p = 0.74), we observed
a trend for more severe prognosis of the disease in males
with a shorter time to death or lung transplantation (Fig-
Figure 1 Age at PAH diagnosis in females and males according to BMPR2 mutation status. BMPR2: bone morphogenetic protein receptor type 
2, PAH: pulmonary arterial hypertension.
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mutation (Figure 3A).
Influence of BMPR2 mutation type on phenotypes
At the time of analysis, 115 patients were carriers of a
BMPR2 mutation. Thirty two (27.8%) had a BMPR2 mis-
sense mutation, 51 (44.3%) a truncating BMPR2 mutation
and 32 (27.8%) other BMPR2 mutations (12 splice defects
and 20 large rearrangements) (Additional file 1). No dif-
ferences in age at diagnosis were observed between
BMPR2 missense mutation carriers, BMPR2 truncating
mutation carriers and patients carrying a large rearrange-
ment or a splice defect in the BMPR2 gene (35.8 ± 16.9,
37.3 ± 14.0 and 33.5 ± 16.3 respectively) (Table 2). Clini-
cal, functional, and hemodynamic characteristics showed
only a lower RAP and a higher CI in BMPR2 missense
mutation carriers, when compared to BMPR2 truncating
mutation carriers (Table 2). No statistically significant
differences were observed in survival and time to death or
lung transplantation between these 3 subgroups of
BMPR2 mutation carriers (Figure 4).
Discussion
In this study, we show that BMPR2 mutation carriers are
younger at diagnosis with a more severe hemodynamic
Figure 2 Time to death or lung transplantation in all patients according to BMPR2 mutation status (A) or gender (B). BMPR2: bone morpho-
genetic protein receptor type 2.
Figure 3 Time to death or lung transplantation in males (A) and in females (B) according to BMPR2 mutation status. BMPR2: bone morpho-
genetic protein receptor type 2.
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ever, we observed a trend for more severe prognosis of
the disease in males, and particularly in male patients
carrying a BMPR2 mutation. This observation is consis-
tent with our recent observation that PAH mortality is
most closely associated with male gender [16]. Moreover,
we compared BMPR2 missense mutation carriers,
BMPR2 truncating mutation carriers and patients carry-
ing a splice defect or a large rearrangement in the BMPR2
gene. We found no influence of mutation type on clinical
phenotypes in BMPR2 mutation carriers with PAH.
Although no significant impact of gender was observed
on age at diagnosis and outcomes in our patient popula-
tion, it should be emphasized that PAH mostly occur in
females, irrespective of BMPR2 mutation status (sex ratio
females/males: 2.4 in BMPR2 mutation non-carriers, and
2.4 in BMPR2 mutation carriers). To explain overrepre-
sentation of female patients it has been suggested that
estrogens and estrogen metabolism might participate in
the pathogenesis of PAH [17,18]. Estrogen is a potent
mitogen of pulmonary vascular smooth muscle cells, and
cytochrome P450 1B1 (CYP1B1), highly expressed in
lung and particularly in endothelial cells, catalyzes the
oxidation of estrogens to 2-hydroxy (2-OHE) and 4-
hydroxy (4-OHE) estrogens. West et al. [17] have showed
significantly decreased transcript levels of CYP1B1 in
affected female compared to unaffected females with a
BMPR2 mutation. They hypothesized that low level of
CYP1B1 might result in increased local concentrations of
estrogens, increasing the risk of PAH. Moreover, in extra-
hepatic tissue, oxidation of estrogens also occurs by
hydroxylation at the C-16 position by other P450
enzymes, predominantly resulting in 16α-hydroxyestrone
(16α-OHE1) which stimulates cellular proliferation by
constitutively activating the estrogen receptor. Austin et
al. [18] demonstrated a decrease of the 2-OHE/16α-
OHE1 ratio in affected female compared to non-affected
females with a BMPR2 mutation. Thus, altered estrogen
metabolism could contribute to the penetrance of PAH in
women and CYP1B1 could be a sex specific modifier
gene.
Secondly, we compared clinical phenotypes of BMPR2
missense mutation carriers, BMPR2 truncating mutation
carriers and patients carrying a splice defect or a large
Table 1: Baseline hemodynamic characteristics of male and female patients carrying a BMPR2 mutation.


















Age at diagnosis, yrs (mean ± SD) 47.8 ± 17.1 34.6 ± 16.8 < 0.0001 47.4 ± 15.8 36.4 ± 14.9 < 0.0001
NYHA
I-II 21 (26.6%) 6 (17.6%) < 0.01 27 (14.4%) 11 (13.6%) 0.90
III 57 (72.2%) 21 (61.8%) 135 (71.8%) 55 (67.9%)
IV 1 (1.3%) 6 (17.6%) 20 (10.6%) 10 (12.3%)
Six-minute walk test distance, m 394 ± 96 377 ± 98 0.49 328 ± 119 343 ± 102 0.35
mPAP, mmHg 57 ± 14 63 ± 13 0.03 56 ± 14 62 ± 13 0.0007
RAP, mmHg 8 ± 5 8 ± 6 0.81 8 ± 5 8 ± 5 0.70
PCWP, mmHg 9 ± 3 8 ± 3 0.39 8 ± 3 8 ± 3 0.84
CI, L/min/m2 2.71 ± 0.83 2.17 ± 0.60 0.0003 2.45 ± 0.66 2.07 ± 0.62 < 0.0001
PVRi, mmHg/L/min/m2 19.6 ± 9.3 21.9 ± 13.5 0.29 20.5 ± 8.5 25.1 ± 11.1 0.0015
SvO2, % 67 ± 8 59 ± 9 0.0015 61 ± 10 59 ± 10 0.09
Acute vasodilator responders, % 9 (11.4%) 1 (2.9%) 0.20 27 (14.4%) 1 (1.2%) < 0.01
BMPR2: bone morphogenetic protein receptor type 2, PAH: pulmonary arterial hypertension, NYHA = New York Heart Association, mPAP = mean 
pulmonary artery pressure, RAP = right atrial pressure, PCWP = pulmonary capillary wedge pressure, CI = cardiac index, PVRi = indexed pulmonary 
vascular resistance, SvO2 = mixed venous oxygen saturation, NO = nitric oxide.
Results are expressed as mean ± SD
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leagues [10] showed that PAH patients with missense
mutations in BMPR2 gene had more severe disease than
patients with truncating mutation with a significant
younger age at diagnosis and a shorter survival from diag-
nosis to death or lung transplantation, we did not find any
influence of mutation type on disease pattern or natural
history among patients with BMPR2 mutation in the
French PAH network. Austin and colleagues [10] hypoth-
esized that this difference may be due to the fact that
truncating mutations are degraded by nonsense-medi-
ated decay (NMD), a mRNA surveillance mechanism that
detects and degrades mRNA transcripts containing pre-
mature termination codons (PTCs), leaving only the wild-
type mRNA detectable. By contrast, missense mutations
escape NMD resulting in stable transcript that may pro-
duce dominant negative proteins [19,20]. Because some
truncating mutations escape NMD, Austin et al. con-
firmed the activity of NMD pathway in BMPR2 truncat-
ing mutation carriers. BMPR2 truncating mutations
escaping NMD pathway may represent a minority of
cases, with only 7 out of the 62 BMPR2 truncating muta-
tion carriers escaping NMD in this study [10]. Indeed,
PTCs located more than 55 nucleotides upstream the last
exon escape NMD. Analysis of all the truncating muta-
tions in the French PAH network showed that 9 out of the
51 BMPR2 truncating mutation carriers had mutations
predicted to escape NMD (Additional file 1). Neverthe-
less, if we excluded these 9 patients from the analysis of
impact of BMPR2 mutation type on clinical outcomes, no
significant differences were seen between BMPR2 mis-
sense mutation carriers, BMPR2 truncating mutation
carriers and patients carrying a splice defect or a large
rearrangement in BMPR2 gene. However, this analysis
cannot include all BMPR2 mutations that could poten-
tially escape NMD, because it has been demonstrated
that truncating mutation may also escape NMD pathway
by reinitiation of translation by use of an alternative
translation start site downstream the PTC, producing a
BMPRII protein of a lower molecular weight [19,20].
Indeed, other factors may influence the relation between
BMPR2 mutation type and phenotype of PAH. It has been
demonstrated that the level of expression of the wild-type
BMPR2 allele may influence the clinical development of
PAH in carriers of truncating BMPR2 mutations [21].
Moreover, different missense BMPR2 mutations could
lead to different level of BMPRII protein expression on
cell surface, depending on the level of cytosolic retention
of BMPR-II transcript [22,23]. All these factors may
explain the difficulty to correlate severity and penetrance
of PAH to the BMPR2 mutation type.
The differences observed between our data and those
reported by Austin et al. related to gender, may be
explained by a selection bias with a low number of PAH
patients without a BMPR2 mutation in the cohort pub-
lished by Austin et al. (only 10 male BMPR2 mutation
non-carriers as compared to 79 in the French PAH Net-
work). This low number of male patients not carrying a
BMPR2 mutation may be due to a preferential recruit-
ment of patients with a family history of PAH in the study
by Austin. Indeed, 74% of their patients had such a family
history, as compared to 22% in the cohort of New York
Presbyterian Pulmonary Hypertension Center [5] and
20% in the French PAH network [6]. This resulted to 72%
of PAH patients carrying a BMPR2 mutation in the
cohort reported by Austin and colleagues, as compared to
17% in the cohort from the New York Presbyterian Pul-
monary Hypertension Center [5], and 25% in the French
PAH network [6]. The lower number of BMPR2 mutation
carriers in the cohort from the New York Presbyterian
Pulmonary Hypertension Center [5] could be explained
by the fact that patients with a considered idiopathic PAH
were not screened for large rearrangement of BMPR2. In
the French PAH network, all patients with idiopathic or
familial PAH were screened for point mutations and large
rearrangements of BMPR2 gene, to avoid selection bias.
The familial clustering in the French PAH network may
explain the differences observed between our data and
those reported by Austin et al. Indeed, familial clustering
could impact data in terms of genes and environmental
interactions that may alter disease expression beyond
that of a single gene mutation. In contrast, in the French
PAH network, 81 out of the 115 BMPR2 mutation carri-
ers (70.5%) were the only cases reported in their families,
while 14 families had 2 cases reported and 2 families had
3 cases reported. Thus the majority of PAH cases we
Figure 4 Influence of BMPR2 mutation types on clinical outcomes 
of PAH patients. Time to death or lung transplantation in BMPR2 mis-
sense mutation carriers, BMPR2 truncating mutation carriers and pa-
tients carriers of a large rearrangement or a splice defect. BMPR2: bone 
morphogenetic protein receptor type 2.
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and familial clustering represented only a minority of
reported cases.
Finally, PAH patients with a family history of PAH with-
out identification of either BMPR2 or ACVRL1 mutation
(n = 13) were excluded from the analysis in order to limit
the risk of misclassification, although their clinical and
hemodynamic characteristics were broadly similar to
those of BMPR2 mutation carriers (age at PAH diagnosis
38.9 ± 12.5 yrs, mPAP 64 ± 13 mmHg, PVRi 25.9 ± 9.5
mmHg/L/min/m²). Moreover, ACVRL1 and Endoglin are
two other genes well known to predispose to PAH. How-
ever, similar approach was not possible in ACVRL1 and
Endoglin mutation carriers because the number of
patients was too low (1 male and 8 female ACVRL1 muta-
tion carriers, and only one patient with an Endoglin
mutation).
In conclusion, our data indicate that mutation type has
no influence on disease pattern or natural history among
patients with BMPR2 mutations. However BMPR2 muta-
tion carriers (males or females) are younger at diagnosis
with a similar evolution of the disease than non-carriers,
leading to a younger age at death of BMPR2 mutation car-
riers compared to non-carriers.
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BMPR2 truncating mutation 
carriers
n = 51




yrs (mean ± SD)
35.8 ± 16.9 37.3 ± 14.0 33.5 ± 16.3
NYHA
I-II 5 (15.6%) 5 (9.8%) 7 (21.8%)
III 21 (65.6%) 37 (72.5%) 18 (56.3%)
IV 3 (9.4%) 7 (13.7%) 6 (18.8%)
Six-minute walk
test distance, m
382 ± 107 351 ± 91 325 ± 109
mPAP, mmHg 63 ± 14 62 ± 12 62 ± 13
RAP, mmHg 6 ± 5* 9 ± 5 8 ± 5
PCWP, mmHg 8 ± 3 7 ± 2 8 ± 4
CI, L/min/m2 2.31 ± 0.68¶ 1.94 ± 0.41 2.16 ± 0.75
PVRi, mmHg/L/min/
m2
24.9 ± 10.8 25.0 ± 10.5 22.5 ± 14.9
SvO2, % 60 ± 9 57 ± 10 60 ± 9
Acute vasodilator
responders, %
1(3.1%) 1 (1.9%) 0.9
*p = 0.02 compared to BMPR2 truncating mutation carriers
¶p = 0.01 compared to BMPR2 truncating mutation carriers
BMPR2: bone morphogenetic protein receptor type 2, PAH: pulmonary arterial hypertension, NYHA = New York Heart Association, mPAP = mean 
pulmonary artery pressure, RAP = right atrial pressure, PCWP = pulmonary capillary wedge pressure, CI = cardiac index, PVRi = indexed pulmonary 
vascular resistance, SvO2 = mixed venous oxygen saturation, NO = nitric oxide.
Results are expressed as mean ± SD
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